Alaunos Prices $1.12M Registered Direct Offering
(RTTNews) - Alaunos Therapeutics, Inc. (TCRT) announced that it entered into definitive agreements with institutional investors for a registered direct offering of 380,469 shares of common stock and pre-funded warrants to purchase up to 386,654 shares.
The securities were priced at $1.46 per share, generating aggregate gross proceeds of approximately $1.12 million before deducting placement agent fees and other offering expenses.
The offering was priced at-the-market under Nasdaq rules and is expected to close on or about September 21, 2026, subject to customary closing conditions.
Alaunos said it plans to use the net proceeds primarily for general working capital and corporate purposes.
Dawson James Securities is acting as the sole placement agent for the offering.
The securities are being offered pursuant to an effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission.
Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics, including ALN1003, an oral small-molecule candidate being evaluated as a potential non-hormonal, non-incretin approach for obesity and metabolic disorders.
TCRT has traded between $1.28 and $4.59 over the past year. The stock closed Thursday's trading at $1.60, up 25.00%. In pre-market trading the stock is at $1.44, down 8.13%.
